Observational Study on Patients With Rasmussen Encephalitis Treated With Adalimumab: Efficacy and Tolerance in the Short and Long Term
Status: Recruiting
Location: See all (16) locations...
Intervention Type: Other
Study Type: Observational
SUMMARY
Since the initial study of cases reported between 2009 and 2015, adalimumab has become in France the immunomodulatory reference treatment used after failure of corticosteroids and immunoglobulins before a possible recourse to the hemispherotomy. This observational study is intended to document the long-term efficacy and safety of Adalimumab therapy in patients with Rasmussen encephalitis.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 2
Healthy Volunteers: f
View:
• Confirmed diagnosis of Rasmussen Encephalitis
• Patient aged more than 2 years
• Compliant treatment with adalimumab
Locations
Other Locations
France
Chu de Bordeaux
NOT_YET_RECRUITING
Bordeaux
Chu Brest
NOT_YET_RECRUITING
Brest
Chru de Lille
NOT_YET_RECRUITING
Lille
Chu Limoges
NOT_YET_RECRUITING
Limoges
Hospices Civils de Lyon
NOT_YET_RECRUITING
Lyon
Service Neuropédiatrie
RECRUITING
Marseille
Chu Montpellier
NOT_YET_RECRUITING
Montpellier
Chu de Nancy
NOT_YET_RECRUITING
Nancy
Chu Necker Ap-Hp
NOT_YET_RECRUITING
Paris
Chu Pitie Salpietriere Ap-Hp
NOT_YET_RECRUITING
Paris
Chu Robert Debre
NOT_YET_RECRUITING
Paris
Fondation Adolphe de Rothshild
NOT_YET_RECRUITING
Paris
Chu de Rennes
NOT_YET_RECRUITING
Rennes
Chu Strasbourg
NOT_YET_RECRUITING
Strasbourg
Chu Toulouse
NOT_YET_RECRUITING
Toulouse
Chru de Tours
NOT_YET_RECRUITING
Tours
Contact Information
Primary
Anne Lépine
anne.lepine@ap-hm.fr
0491387267
Backup
DRS AP-HM
drci@ap-hm.fr
0491381499
Time Frame
Start Date: 2020-04-21
Estimated Completion Date: 2025-10
Participants
Target number of participants: 40
Related Therapeutic Areas
Sponsors
Leads: Assistance Publique Hopitaux De Marseille